Edmund Chang, PhD

Annexon Biosciences
Brisbane, CA, United States

Edmund Chang, PhD is Director, Clinical Biomarkers at Annexon Biosciences. He received his BA in Molecular and Cellular Biology from the University of California, Berkeley, CA, and then went on to earn a PhD in Molecular Endocrinology/Toxicology from the University of Illinois in Champaign, IL. Dr. Chang then completed postdoctoral training at Baylor College of Medicine and Texas Children's Hospital, both in Houston, after which he spent almost six years providing his expertise and analysis in support of the Translational Science and Computational Biology teams at Kite Pharma, Tessera Therapeutics, Takeda and Hummingbird Bioscience before taking on his current role at Annexon Biosciences.

Disclosure information not submitted.

Presentation(s):

• 0648: Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients

  Sunday, November 13, 2022
  9:00 AM – 10:30 AM Eastern Time